Experimental drug may benefit some patients with rare form of ALS
NEW YORK, NY (May 22, 2025)--When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he’s unwaveringly honest. “Patients always ask me, “What can I hope to get out of this?” Shneider says. “And I always say, in most clinical trials, our hope is that we can slow the disease or maybe even halt progression.”
So it was a big surprise when some of the patients treated with an experimental drug—a therapy that emerged from Shneider’s research efforts—showed improvements.
“When testing new drugs for ALS, we do not expect to ...